210037-76-6

Basic information

• Product Name: methyl 4-cyano-3-methoxybenzoate
• Synonyms: methyl 4-cyano-3-methoxybenzoate
• CAS NO: 210037-76-6
• Molecular Formula: C₁₀H₉NO₃
• Molecular Weight: 191.18336
• Mol File: 210037-76-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 4-cyano-3-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-cyano-3-methoxybenzoate(210037-76-6)
• EPA Substance Registry System: methyl 4-cyano-3-methoxybenzoate(210037-76-6)

Safety Data

• Hazardous Substances Data: 210037-76-6(Hazardous Substances Data)

Upstream product

• 6520-87-2 methyl 4-cyano-3-hydroxybenzoate 
• 74-88-4 methyl iodide 
• 3556-83-0 methyl 4-methyl-3-methoxybenzoate 
• 70264-94-7 methyl 4-(bromomethyl)-3-methoxybenzoate 
• 2150-38-1 methyl 3,4-dimethoxybenzoate 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 186581-53-3 diazomethane 
• 17100-63-9 methyl 4-bromo-3-methoxybenzoate 
• 106291-80-9 methyl 4-bromo-3-hydroxybenzoate 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 74733-24-7 4-formyl-3-methoxybenzoic acid methyl ester 

Downstream Products

• 5156-00-3 2-methoxyterephthalic acid 
• 210037-77-7 4-hydroxymethyl-2-methoxy-benzonitrile 
• 102362-00-5 4-Cyano-3-methoxybenzoic acid 
• 102362-01-6 3-Methoxy-4-cyanobenzoyl chloride 

Relevant articles and documents

Arene Cyanation via Cation-Radical Accelerated-Nucleophilic Aromatic Substitution

Herein we describe a cation radical-accelerated-nucleophilic aromatic substitution (CRA-SNAr) of alkoxy arenes utilizing a highly oxidizing acridinium photoredox catalyst and acetone cyanohydrin, an inexpensive and commercially available cyanide source. This cyanation is selective for carbon-oxygen (C-O) bond functionalization and is applicable to a range of methoxyarenes and dimethoxyarenes. Furthermore, computational studies provide a model for predicting regioselectivity and chemoselectivity in competitive C-H and C-O cyanation of methoxyarene cation radicals.

FUSED QUINOLINE DERIVATIVE AND USE THEREOF

The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8,R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7and R8,R8 and R9,and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.